Month: October 2023

Financial technology company empowering better financial outcomes for everyday Americans ranks as #28 fastest-growing company ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “we,” “our” or “us”), a technology company enabling bank, retail, and healthcare partners to offer more inclusive financial services, is proud to announce it has been named one of Fortune’s 100 Fastest-Growing Companies for the third consecutive year. Atlanticus was recognized on Fortune’s list in 2021 as the #1, in 2022 as the #4, and now in 2023 as the #28 fastest-growing company. Atlanticus is one of only six companies returning to Fortune’s Fastest-Growing Companies list for a third consecutive year. The annual list, now in its 38th year, ranked qualifying companies based on growth in revenue, profits,...

HAMILTON, Ontario, Oct. 31, 2023 (GLOBE NEWSWIRE) — Reliq Health Technologies Inc. (TSXV:RHT or OTC:RQHTF or WKN:A2AJTB) (“Reliq” or the “Company”), a rapidly growing global healthcare technology company that develops innovative Virtual Care solutions for the multi-billion dollar Healthcare market, today announced that, as a result of delays to its audit, the Company’s annual financial statements and accompanying management’s discussion and analysis for the fiscal year ended June 30, 2023 (the “Annual Filings”) were not finalized by October 30, 2023, being the date that such filings are due under applicable Canadian securities law requirements. The Company has applied for, and has been granted, a management cease trade order (the “MCTO”) by the British Columbia Securities Commission. The Company has been delayed...

GREENWOOD VILLAGE, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) — Advanced Emissions Solutions, Inc. (NASDAQ: ADES) (the “Company” or “ADES”) today announced the Company expects to release its third quarter 2023 financial results and file its Quarterly Report on Form 10-Q for the period ended September 30, 2023 after market close on Wednesday, November 8, 2023. A conference call to discuss the Company’s financial performance is scheduled to begin at 9:00 a.m. Eastern Time on Thursday, November 9, 2023. The conference call webcast information will be available via the Investor Resources section of ADES’s website at www.advancedemissionssolutions.com. Interested parties wishing to join the call may dial (877)408-0890 (Domestic) or +1(201)389-0918 (International) or may join by webcast at http://www.webcast-eqs.com/ADES110923....

SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) — FLJ Group Limited (NASDAQ: FLJ) (“FLJ” or the “Company”), announced that it entered into an equity transfer agreement on October 31, 2023 to sell all of its equity interest in its indirectly wholly-owned subsidiary Haoju (Shanghai) Artificial Intelligence Technology Co., Ltd. ( the “WFOE”), a limited company incorporated under the laws of PRC, to Wangxiancai Limited, a limited company incorporated under the laws of Hong Kong, for nominal consideration (the “Disposal”). The Disposal was completed on the same date. Through the WFOE and the WFOE’s subsidiaries, the Company carried out its long-term apartment rental business (the “Disposed Business”). The Disposed Business contributed substantially all revenue and held substantially all of the assets of the Company prior to the Disposal....

-Exa-cel PDUFA target action date is December 8, 2023 for severe sickle cell disease (SCD)- ZUG, Switzerland and BOSTON, Oct. 31, 2023 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee meeting for exagamglogene autotemcel (exa-cel) for the treatment of SCD in people ages 12 and older with recurrent vaso-occlusive crises (VOCs). Exa-cel is the first potential therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals. If approved, exa-cel could be the first genetic therapy available to approximately twenty thousand people with severe SCD in the U.S. The FDA granted priority review for exa-cel in the treatment of people with SCD and assigned a Prescription...

– Funding underpins doubling of production capacity to 20,000 tpa at existing Riverside (Chattanooga) facility –– Recent Chinese export controls on graphite highlight the importance of US based suppliers such as NOVONIX – BRISBANE, Australia, Nov. 01, 2023 (GLOBE NEWSWIRE) — NOVONIX Limited (NASDAQ: NVX, ASX: NVX) (“NOVONIX” or the “Company”), a leading battery materials and technology company, today announced that its NOVONIX Anode Materials division finalized its US$100 million grant award from the U.S. Department of Energy (DOE) to expand domestic production of high-performance, synthetic graphite anode materials at its Riverside facility in Chattanooga, Tennessee. On 20 October 2022, NOVONIX announced its selection to enter negotiations for US$150 million in grant funding to support the construction...